Hong Jaewoo, Wuest Todd R, Min Yongfen, Lin P Charles
Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Cancers (Basel). 2019 Oct 25;11(11):1653. doi: 10.3390/cancers11111653.
Oxygen sensing is crucial for adaptation to variable habitats and physiological conditions. Low oxygen tension, or hypoxia, is a common feature of solid tumors, and hypoxic tumors are often more aggressive and resistant to therapy. Here we show that, in cultured mammalian cells, hypoxia suppressed lysosomal acidification/activation and receptor tyrosine kinase (RTK) degradation. Hypoxia down-regulated mTORc1, reducing its ability to activate transcription factor EB (TFEB), a master regulator of V-ATPase, the lysosomal proton pump. Hypoxia prevented epidermal growth factor receptor (EGFR) degradation in tumor tissues, whereas activation of lysosomes enhanced tumor cell response to anti-EGFR treatment. Our results link oxygen tension and lysosomal activity, provide a molecular explanation of the malignant phenotype associated with hypoxic tumors, and suggest activation of lysosomes may provide therapeutic benefit in RTK-targeted cancer therapy.
氧气感知对于适应多变的栖息地和生理条件至关重要。低氧张力,即缺氧,是实体瘤的一个常见特征,而缺氧肿瘤通常更具侵袭性且对治疗有抗性。在此我们表明,在培养的哺乳动物细胞中,缺氧会抑制溶酶体酸化/激活以及受体酪氨酸激酶(RTK)降解。缺氧下调了mTORc1,降低了其激活转录因子EB(TFEB)的能力,TFEB是溶酶体质子泵V-ATPase的主要调节因子。缺氧阻止了肿瘤组织中表皮生长因子受体(EGFR)的降解,而溶酶体的激活增强了肿瘤细胞对抗EGFR治疗的反应。我们的结果将氧张力与溶酶体活性联系起来,为与缺氧肿瘤相关的恶性表型提供了分子解释,并表明溶酶体的激活可能在RTK靶向癌症治疗中带来治疗益处。